|
|
|
| home > white papers > Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences - Myoderm |
|
|
 WHITE PAPERS |
|
Myoderm
|
|
Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences
|
|
Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Aptar Pharma Co Organizer and Diamond Sponsor of RDD Europe 2019 Conference in Estoril Portugal
Crystal Lake, Illinois, March 21, 2019
Aptar Pharma, the leader in respiratory drug delivery systems, is proud to announce its coorganization and diamond sponsorship of the Respiratory Drug Delivery (RDDŽ) Europe 2019 scientific conference, connecting pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal from May 7-10, 2019.
More info >> |
|
 |
White Papers |
 |
|
Keeping Abreast of the Competitive Environment in Clinical Development
Thomson Reuters
Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >> |
|
 |
Industry Events |
 |
ASGCT 22nd Annual Meeting
29 April - 2 May 2019, Washington Hilton, Washington, D.C
The 2019 ASGCT Annual Meeting is expected to be the largest in Society
history, eclipsing the mark set by the 2018 meeting just last year. Join more
than 3,500 researchers, clinicians, advocates, and industry leaders in
discovering the latest science and technology surrounding gene and cell
therapy.
More info >> |
|
|
|
